Visible results seen in real-world patients
In DUPIXENT clinical trials including adults, the primary endpoint was the proportion of subjects with an Investigator's Global Assessment (IGA) of 0 (clear) or 1 (almost clear) and ≥2-point improvement at Week 16.1
Actual patients treated with DUPIXENT. Not clinical trial patients. Patients 2 and 3 were on concomitant therapies, such as TCS, phototherapy, etc, at their prescribing physician’s discretion. Scoring was designated by the treating physician. Because all 3 patients were real-world patients, there may be other factors influencing their treatment results, and individual results may vary.
Patient 1: achieved a 3-point improvement in IGA
to see results




Patient 2: achieved a 3-point improvement in IGA
to see results




Patient 3: achieved a 4-point improvement in IGA
to see results




A clinical responder was defined as a patient achieving IGA 0 or 1 and at least a 2-point improvement from baseline.1
Significantly clearer skin
CHRONOS: Concomitant Therapy With TCS
Significant skin clearance was also demonstrated with DUPIXENT in monotherapy trials1,4
aResponder was defined as a subject with IGA 0 or 1 (clear or almost clear) with a reduction of ≥2 points from baseline on a 0-4 IGA scale at Week 16 in all
trials (primary efficacy outcome) and at Week 52 in CHRONOS (other endpoint).1
bIn the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders.1
cFull Analysis Set includes all subjects randomized.1
dIn CHRONOS, as needed, subjects received topical calcineurin inhibitors for problem areas only, such as the face, neck, and intertriginous and genital areas.1
eWeek 52 data were limited to patients completing 52 weeks as of the cutoff date.2
IGA assesses the overall severity of the clinical signs of atopic dermatitis2
A 0- to 4-point scoring system of the overall severity of atopic dermatitis skin lesions2
Severe
Disease
Severe erythema and severe
papulation/infiltration
Moderate
Disease
Moderate erythema and moderate
papulation/infiltration
Mild
Disease
Mild erythema and mild
papulation/infiltration
Almost
Clear
Just perceptible erythema, and
just perceptible papulation/infiltration
Clear
No inflammatory signs of atopic dermatitis
A clinical responder
was defined as a
patient achieving IGA 0
or 1 and at least a
2-point improvement
from baseline1IGA, Investigator's Global Assessment.
Example representation of IGA scoring.
Not an actual patient.